Menu
Search
|

Menu

Close
X

Dermira Inc DERM.OQ (NASDAQ Stock Exchange Global Select Market)

12.12 USD
+0.44 (+3.77%)
As of 4:00 PM EDT
chart
Previous Close 11.68
Open 11.68
Volume 147,962
3m Avg Volume 204,258
Today’s High 12.42
Today’s Low 11.68
52 Week High 31.42
52 Week Low 6.99
Shares Outstanding (mil) 42.03
Market Capitalization (mil) 500.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
39
FY17
5
FY16
23
FY15
7
EPS (USD)
FY18
-1.988
FY17
-7.366
FY16
-2.768
FY15
-2.886
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
11.97
6.55
Price to Book (MRQ)
vs sector
4.45
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
249.28
14.15
LT Debt to Equity (MRQ)
vs sector
249.28
11.31
Return on Investment (TTM)
vs sector
-59.34
12.83
Return on Equity (TTM)
vs sector
-131.33
14.95

EXECUTIVE LEADERSHIP

Thomas Wiggans
Chairman of the Board, Chief Executive Officer, Co-Founder, Since 2014
Salary: $525,000.00
Bonus: --
Christopher Griffith
Senior Vice President - Corporate Development and Strategy, Founder, Since 2017
Salary: $284,900.00
Bonus: --
Luis Pena
Co-Founder, Chief Development Officer, Since 2016
Salary: $382,400.00
Bonus: --
Andrew Guggenhime
Chief Financial Officer, Since 2018
Salary: $380,290.00
Bonus: --
Christopher Horan
Chief Technical Operations Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

275 Middlefield Rd Ste 150
MENLO PARK   CA   94025-4008

Phone: +1650.4217200
Site: dermira.com/

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

SPONSORED STORIES